annual meeting program - American Society of Clinical Oncology

Tuesday, June 8, 2010
Brd. 7 Treatment of the elderly when cure is the goal: The influence of age on
treatment selection and efficacy for stage III non-small cell lung cancer
(NSCLC). (Abstract #7014)
L. E. Coate, C. Massey, A. J. Hope, A. Pierre, A. Bezjak, N. B. Leighl,
G. E. Darling, A. Sun, S. Keshavjee, F. A. Shepherd
Brd. 8 A multinational pooled analysis of 434 cases of stage I non-small cell lung
cancer (NSCLC) treated with volumetrically image-guided (VIGRT)
stereotactic lung radiotherapy (SBRT): Results from the Elekta Collaborative
Lung Research Group. (Abstract #7015)
I. S. Grills, A. J. Hope, M. Guckenberger, L. L. Kestin, M. Werner-Wasik, D. Yan,
J. Sonke, J. Bissonnette, Y. Xiao, J. Belderbos
Brd. 9 Thoracic radiation therapy in locally advanced NSCLC patients (pts) with
EGFR mutations. (Abstract #7016)
R. H. Mak, E. Doran, A. Muzikansky, J. Kang, N. C. Choi, H. Willers,
D. M. Jackman, L. V. Sequist
Brd. 10 Utilization of adjuvant therapy among completely resected non-small cell
lung cancer (NSCLC) patients in the National Comprehensive Cancer
Network (NCCN) Outcomes Database Project. (Abstract #7017)
C. Zornosa, R. Mamet, M. E. Reid, D. S. Ettinger, G. A. Otterson, M. S. Rabin,
J. Hayman, J. C. Niland, K. Pisters, NCCN Oncology Outcomes Database
Non-small Cell Lung Cancer Disease-specific Executive Committee
Brd. 11 Adoption of adjuvant chemotherapy for non-small cell lung cancer:
A population-based outcomes study. (Abstract #7018)
C. M. Booth, F. A. Shepherd, Y. Peng, G. E. Darling, G. Li, W. Kong,
W. J. Mackillop
Brd. 12 A phase III adjuvant vinorelbine plus cisplatin (NP) versus NP plus endostar
(NPE) in patients (pts) with completely resected stage IB-IIIA non-small cell
lung cancer (NSCLC): An interim preliminary result. (Abstract #7019)
H. Jie, Z. Xiangru, B. Han, Y. Liu, Q. Wang, S. Xu, Y. Sheng, Q. Li, S. Wu,
C. Chen
Brd. 13 IFCT-GFPC-0701 MAPS trial, a multicenter randomized phase II/III trial of
pemetrexed-cisplatin with or without bevacizumab in patients with malignant
pleural mesothelioma. (Abstract #7020)
G. Zalcman, J. Margery, A. Scherpereel, P. Astoul, I. Monnet, B. J. Milleron,
L. M. Paule, M. André, D. Moro-Sibilot, J. Mazieres, on behalf of IFCT
Brd. 14 Validation of the lung cancer staging system revisions using a large
prospective clinical trial database (ACOSOG Z0030). (Abstract #7021)
J. J. Fibla, S. D. Cassivi, P. A. Decker, M. S. Allen, G. E. Darling, R. J. Landreneau,
R. J. McKenna Jr., D. R. Jones, R. I. Inculet, J. B. Putnam, ACOSOG Z0030 Study
Group
Brd. 15 The impact of stage migration on survival after resection in the UICC 7 TNM
classification of lung cancer. (Abstract #7022)
J. P. Van Meerbeeck, K. Chansky, P. Goldstraw, IASLC Staging Committee
Brd. 16 Prognostic significance of the number of tumor (�) N2 nodes in N2 stage IIIA
non-small cell lung cancer after curative resection. (Abstract #7023)
C. Yoo, S. Yoon, D. Lee, C. Suh, J. Lee, S. Park, D. Kim, Y. Kim, W. Kim, S. Kim
Brd. 17 RTOG 0229: A phase II trial of neoadjuvant therapy with concurrent
chemotherapy and high-dose radiotherapy (XRT) followed by resection and
consolidative therapy for LA-NSCLC. (Abstract #7024)
M. Suntharalingam, R. Paulus, M. J. Edelman, M. Krasna, W. Burrows, E. Gore,
S. Yom, H. Choy
431
TUESDAY